NCT03876769 2026-04-17
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT06785818 2026-02-23
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis
Recruiting
NCT05460533 2026-02-04
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03610724 2024-06-20
BIANCA
Novartis
Phase 2 Completed
NCT02435849 2024-02-13
ELIANA
Novartis
Phase 2 Completed
NCT04156659 2023-03-09
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Novartis
Phase 2 Withdrawn
NCT04225676 2023-01-30
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 2 Terminated
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed
NCT02167360 2017-02-14
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn